Developing new therapies for Non-Small Cell Lung Cancer using engineered aptamers
Molecular engineering and systematic evaluation of bispecific aptamers to develop potent and efficacious therapies for the immunomodulation of Non-Small Cell Lung Cancer
This study is looking at new treatments for Non-Small Cell Lung Cancer that use special molecules to help your immune system fight the cancer more effectively, aiming to make the treatment work better and cause fewer side effects.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Missouri-Columbia NIH-funded |
| Lab location | 1 site (Columbia, United States) |
| Project ID | NIH-10918084 on NIH RePORTER |
What this research studies
This research focuses on creating and testing bispecific aptamers, which are specialized molecules designed to target and modulate the immune response against Non-Small Cell Lung Cancer (NSCLC). By leveraging aptamer technology, the study aims to develop therapies that can effectively overcome challenges such as tumor resistance and side effects associated with current treatments. Patients may benefit from these therapies as they are designed to be more specific and less immunogenic than traditional antibodies, potentially leading to better outcomes with fewer adverse effects.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Non-Small Cell Lung Cancer who may not have responded well to existing therapies.
Not a fit: Patients with other types of cancer or those who are not diagnosed with Non-Small Cell Lung Cancer may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide patients with more effective and safer treatment options for Non-Small Cell Lung Cancer.
How similar studies have performed: While the use of aptamers in cancer therapy is a promising area, this specific approach is relatively novel and has not been extensively tested in the context of NSCLC.
Where this research is happening
Columbia, United States
- University of Missouri-Columbia — Columbia, United States (Active)
Researchers
- Principal investigator: Thomas, Brian J — University of Missouri-Columbia
- Study coordinator: Thomas, Brian J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.